Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science